- Home
- EWCZ vs TSHA Comparison
EWCZ vs TSHA Comparison
Compare EWCZ & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- TSHA
- Stock Information
- Founded
- EWCZ 2004
- TSHA 2019
- Country
- EWCZ United States
- TSHA United States
- Employees
- EWCZ N/A
- TSHA N/A
- Industry
- EWCZ Package Goods/Cosmetics
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- TSHA Health Care
- Exchange
- EWCZ Nasdaq
- TSHA Nasdaq
- Market Cap
- EWCZ 300.3M
- TSHA 356.7M
- IPO Year
- EWCZ 2021
- TSHA 2020
- Fundamental
- Price
- EWCZ $4.22
- TSHA $1.65
- Analyst Decision
- EWCZ Buy
- TSHA Strong Buy
- Analyst Count
- EWCZ 7
- TSHA 8
- Target Price
- EWCZ $6.07
- TSHA $6.63
- AVG Volume (30 Days)
- EWCZ 684.8K
- TSHA 1.7M
- Earning Date
- EWCZ 03-11-2025
- TSHA 05-13-2025
- Dividend Yield
- EWCZ N/A
- TSHA N/A
- EPS Growth
- EWCZ 29.60
- TSHA N/A
- EPS
- EWCZ 0.22
- TSHA N/A
- Revenue
- EWCZ $216,916,000.00
- TSHA $8,333,000.00
- Revenue This Year
- EWCZ $5.65
- TSHA N/A
- Revenue Next Year
- EWCZ $4.11
- TSHA N/A
- P/E Ratio
- EWCZ $19.33
- TSHA N/A
- Revenue Growth
- EWCZ N/A
- TSHA N/A
- 52 Week Low
- EWCZ $2.72
- TSHA $1.19
- 52 Week High
- EWCZ $13.17
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- EWCZ 29.01
- TSHA 43.73
- Support Level
- EWCZ $3.83
- TSHA $1.59
- Resistance Level
- EWCZ $4.29
- TSHA $1.87
- Average True Range (ATR)
- EWCZ 0.37
- TSHA 0.10
- MACD
- EWCZ -0.03
- TSHA -0.01
- Stochastic Oscillator
- EWCZ 47.83
- TSHA 8.93
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.